688247 宣泰医药
交易中 10-20 10:00:57
资讯
新帖
简况
宣泰医药（688247）披露2026年半年度权益分派实施公告，10月19日股价下跌2.6%
证券之星 · 10-19 17:30
宣泰医药（688247）披露2026年半年度权益分派实施公告，10月19日股价下跌2.6%
股市必读：宣泰医药新发布《关于股东无偿捐赠部分公司股份完成过户的公告》
证券之星 · 10-19 02:24
股市必读：宣泰医药新发布《关于股东无偿捐赠部分公司股份完成过户的公告》
宣泰医药：Finer捐赠20万股完成过户
同花顺 · 10-15
宣泰医药：Finer捐赠20万股完成过户
宣泰医药（688247）10月8日主力资金净卖出498.32万元
证券之星 · 10-09
宣泰医药（688247）10月8日主力资金净卖出498.32万元
宣泰医药（688247）9月28日主力资金净卖出200.76万元
证券之星 · 09-29
宣泰医药（688247）9月28日主力资金净卖出200.76万元
宣泰医药（688247）9月23日主力资金净买入699.18万元
证券之星 · 09-24
宣泰医药（688247）9月23日主力资金净买入699.18万元
宣泰医药：9月15日召开业绩说明会，投资者参与
证券之星 · 09-16
宣泰医药：9月15日召开业绩说明会，投资者参与
宣泰医药新提交“宣佳泰”、“宣家泰”等2件商标注册申请
证券之星 · 09-15
宣泰医药新提交“宣佳泰”、“宣家泰”等2件商标注册申请
每周股票复盘：宣泰医药（688247）变更签字注册会计师
证券之星 · 09-13
每周股票复盘：宣泰医药（688247）变更签字注册会计师
宣泰医药（688247）披露变更签字注册会计师公告，9月10日股价下跌3.99%
证券之星 · 09-10
宣泰医药（688247）披露变更签字注册会计师公告，9月10日股价下跌3.99%
宣泰医药：9月3日接受机构调研，国泰海通、农银汇理基金等多家机构参与
证券之星 · 09-07
宣泰医药：9月3日接受机构调研，国泰海通、农银汇理基金等多家机构参与
股市必读：宣泰医药新发布《2026年半年度报告摘要》
证券之星 · 08-31
股市必读：宣泰医药新发布《2026年半年度报告摘要》
每周股票复盘：宣泰医药（688247）股东户数下降3.41%
证券之星 · 08-30
每周股票复盘：宣泰医药（688247）股东户数下降3.41%
宣泰医药（688247）披露2026年半年度报告，8月27日股价上涨0.62%
证券之星 · 08-27
宣泰医药（688247）披露2026年半年度报告，8月27日股价上涨0.62%
宣泰医药(688247.SH)发布半年度业绩，归母净利润2970万元，同比下降34.84%
智通财经 · 08-27
宣泰医药(688247.SH)发布半年度业绩，归母净利润2970万元，同比下降34.84%
宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请
证券之星 · 08-05
宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请
股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》
证券之星 · 08-05
股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》
宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购
智通财经 · 08-03
宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购
每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功
证券之星 · 07-26
每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功
宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准
格隆汇 · 07-24
宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准
加载更多
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、马昔腾坦片、美沙拉秦肠溶缓释片、西格列汀二甲双胍缓释片、格列净二甲双胍缓释片、奥拉帕利片、依西美坦片等。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":8.62,"timestamp":1792461657000,"preClose":8.6,"halted":0,"volume":1267109,"delay":0,"changeRate":0.0023,"floatShares":453000000,"shares":453000000,"eps":0.0698,"marketStatus":"交易中","change":0.02,"latestTime":"10-20 10:00:57","open":8.53,"high":8.68,"low":8.45,"amount":10848300,"amplitude":0.0267,"askPrice":8.62,"askSize":33,"bidPrice":8.61,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.0698,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792467000000},"marketStatusCode":2,"adr":0,"adjPreClose":8.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792459800000,1792467000000],[1792472400000,1792479600000]],"highLimit":9.46,"lowLimit":7.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":2.96,"roa":"--","peRate":123.495702,"roe":"2.27%","epsLYR":0.11,"committee":-0.162963,"marketValue":3908000000,"turnoverRate":0.0028,"status":0,"floatMarketCap":3908000000},"requestUrl":"/m/hq/s/688247/","defaultTab":"news","newsList":[{"id":"2676504973","title":"宣泰医药（688247）披露2026年半年度权益分派实施公告，10月19日股价下跌2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676504973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676504973?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:30","pubTimestamp":1792402259,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，宣泰医药报收于8.6元，较前一交易日下跌2.6%，最新总市值为38.99亿元。该股当日开盘8.77元，最高9.02元，最低8.34元，成交额达6121.22万元，换手率为1.57%。近日，公司发布《2026年半年度权益分派实施公告》。股权登记日为2026年10月22日，除权（息）日和现金红利发放日均为2026年10月23日。差异化分红方案经2025年年度股东会授权，董事会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900022509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676780775","title":"股市必读：宣泰医药新发布《关于股东无偿捐赠部分公司股份完成过户的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676780775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676780775?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:24","pubTimestamp":1792347851,"startTime":"0","endTime":"0","summary":"公司公告汇总关于股东无偿捐赠部分公司股份完成过户的公告上海宣泰医药科技股份有限公司股东Finer Pharma Inc.将其持有的200,000股公司股份捐赠给辽宁省沈阳药科大学教育基金会，用于支持沈阳药科大学的教育发展建设。公司因实施股份回购导致回购股份不参与利润分配，故本次分红构成差异化分红。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675852304","title":"宣泰医药：Finer捐赠20万股完成过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2675852304","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675852304?lang=zh_cn&edition=full","pubTime":"2026-10-15 15:52","pubTimestamp":1792050720,"startTime":"0","endTime":"0","summary":"10月15日，宣泰医药(688247.SH)公告，公司此前披露股东Finer Pharma Inc.拟将其持有的20万股公司股份捐赠给辽宁省沈阳药科大学教育基金会；近日双方已通过非交易过户完成20万股公司股份过户 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261015/c680727439.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261015/c680727439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889125","title":"宣泰医药（688247）10月8日主力资金净卖出498.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674889125?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:36","pubTimestamp":1791506164,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，宣泰医药报收于9.62元，下跌4.66%，换手率1.84%，成交量8.33万手，成交额8098.26万元。近5日资金流向一览见下表：宣泰医药融资融券信息显示，融资方面，当日融资买入764.39万元，融资偿还794.84万元，融资净偿还30.45万元。宣泰医药主营业务：从事高技术壁垒的仿制药的研发、生产、销售,以及制剂CRO/CMO服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671266285","title":"宣泰医药（688247）9月28日主力资金净卖出200.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671266285","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671266285?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:25","pubTimestamp":1790641525,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，宣泰医药报收于9.95元，上涨0.71%，换手率1.73%，成交量7.86万手，成交额7873.37万元。近5日资金流向一览见下表：宣泰医药融资融券信息显示，融资方面，当日融资买入590.91万元，融资偿还594.38万元，融资净偿还3.47万元。宣泰医药主营业务：从事高技术壁垒的仿制药的研发、生产、销售,以及制剂CRO/CMO服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432002","title":"宣泰医药（688247）9月23日主力资金净买入699.18万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432002?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:22","pubTimestamp":1790209363,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，宣泰医药报收于10.25元，上涨2.4%，换手率1.97%，成交量8.92万手，成交额9122.25万元。近5日资金流向一览见下表：宣泰医药融资融券信息显示，融资方面，当日融资买入917.68万元，融资偿还625.86万元，融资净买入291.81万元。宣泰医药主营业务：从事高技术壁垒的仿制药的研发、生产、销售,以及制剂CRO/CMO服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607712","title":"宣泰医药：9月15日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607712","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667607712?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:01","pubTimestamp":1789556477,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月16日宣泰医药发布公告称公司于2026年9月15日召开业绩说明会。）获得日本厚生劳动省批准上市，并顺利承接其商业化阶段CMO生产服务。截至目前，公司已累计助力7款创新药获批上市并落地商业化生产，充分验证了一站式CDMO平台在跨区域创新药项目中的交付能力，行业口碑与市场影响力持续提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600031713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667321691","title":"宣泰医药新提交“宣佳泰”、“宣家泰”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2667321691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667321691?lang=zh_cn&edition=full","pubTime":"2026-09-15 07:22","pubTimestamp":1789428140,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日上海宣泰医药科技股份有限公司新提交“宣佳泰”、“宣家泰”等2件商标注册申请。商标申请详情如下：今年以来上海宣泰医药科技股份有限公司新申请注册商标5件，截止目前公司共持有注册商标166件，另有23件商标尚在注册申请中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500004877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667072085","title":"每周股票复盘：宣泰医药（688247）变更签字注册会计师","url":"https://stock-news.laohu8.com/highlight/detail?id=2667072085","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667072085?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:38","pubTimestamp":1789238292,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，宣泰医药报收于8.56元，较上周的9.11元下跌6.04%。本周，宣泰医药9月8日盘中最高价报9.42元。本周关注点公司公告汇总：宣泰医药变更2026年度签字注册会计师，由张君如接替缪雪。公司公告汇总上海宣泰医药科技股份有限公司于2026年9月11日发布公告，因原签字注册会计师缪雪工作调整，上会会计师事务所指派张君如接替其职务，作为公司2026年度财务报表和内部控制审计的签字注册会计师。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910685","title":"宣泰医药（688247）披露变更签字注册会计师公告，9月10日股价下跌3.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910685","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666910685?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:35","pubTimestamp":1789050915,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，宣泰医药报收于8.9元，较前一交易日下跌3.99%，最新总市值为40.35亿元。近日，上海宣泰医药科技股份有限公司发布公告，因原签字注册会计师缪雪工作调整，上会会计师事务所指派张君如接替其职务，作为公司2026年度财务报表和内部控制审计的签字注册会计师。变更后，签字注册会计师为时英浩和张君如。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000042355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665439111","title":"宣泰医药：9月3日接受机构调研，国泰海通、农银汇理基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665439111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665439111?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:48","pubTimestamp":1788760095,"startTime":"0","endTime":"0","summary":"2026年上半年，公司已有4项产品在6个国家和地区提交注册申请。根据公司经营规划，全年计划完成5项产品申报、力争实现4项产品获批。此外，公司于2024年实施了股份回购，截至目前回购金额与现金分红金额合计已超过1亿元，充分体现了对股东回报的高度重视。今年上半年，公司外销收入为5,940万元，是营收的重要组成部分。目前公司产品已覆盖美国、欧盟、海湾国家、中南美洲、东南亚等多个区域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700013269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","02611","BK0188","688247","BK0012","BK0184","BK0201","BK0276","BK1564","BK1147","BK0239","601211","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663028879","title":"股市必读：宣泰医药新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663028879?lang=zh_cn&edition=full","pubTime":"2026-08-31 07:42","pubTimestamp":1788133331,"startTime":"0","endTime":"0","summary":"公司公告汇总：将于2026年9月15日参加科创板生物制品及CXO行业集体业绩说明会。公司公告汇总2026年半年度报告摘要截至2026年6月30日，公司总资产1,474,983,684.86元，较上年度末增长2.56%；归属于上市公司股东的净资产1,318,847,108.39元，较上年度末增长2.08%。关于新增认定核心技术人员的公告2026年8月26日，公司第三届董事会第三次会议审议通过《关于新增认定核心技术人员的议案》，新增认定贺小玲、潘端锦为公司核心技术人员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663516048","title":"每周股票复盘：宣泰医药（688247）股东户数下降3.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663516048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663516048?lang=zh_cn&edition=full","pubTime":"2026-08-30 05:40","pubTimestamp":1788039622,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，宣泰医药报收于9.49元，较上周的9.76元下跌2.77%。本周，宣泰医药8月26日盘中最高价报10.14元。股本股东变化截至2026年6月30日，宣泰医药股东户数为7693.0户，较3月31日减少272.0户，减幅为3.41%。报告期内实现营业收入19,116.02万元，同比下降12.95%；归母净利润2,970.18万元，同比下降34.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701495","title":"宣泰医药（688247）披露2026年半年度报告，8月27日股价上涨0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701495","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662701495?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:27","pubTimestamp":1787830034,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，宣泰医药报收于9.78元，较前一交易日上涨0.62%，最新总市值为44.34亿元。近日，宣泰医药披露《2026年半年度报告》。报告期内营业收入为191,160,204.92元，同比下降12.95%；利润总额为32,131,658.61元，同比下降37.03%；归属于上市公司股东的净利润为29,701,777.95元，同比下降34.84%；归属于上市公司股东的扣除非经常性损益的净利润为20,377,532.18元，同比下降48.44%。经营活动产生的现金流量净额为85,047,881.61元，同比增长73.64%。研发投入占营业收入的比例为16.74%，较上年同期增加5.04个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977142","title":"宣泰医药(688247.SH)发布半年度业绩，归母净利润2970万元，同比下降34.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977142","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662977142?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:26","pubTimestamp":1787819194,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)披露2026年半年度报告，报告期公司实现营业收入1.91亿元，同比下降12.95%;归母净利润2970万元，同比下降34.84%;扣非归母净利润2038万元，同比下降48.44%;基本每股收益0.07元。公司拟向全体股东每10股派发现金红利0.15元(含税)。业绩变动主要系：受到集采政策持续推进的影响，部分产品价格下调，产品销售收入同比下降，以及报告期内未达到收入确认里程碑节点，研发技术成果转化收入较上年同期减少854.55万元，以上因素导致营业收入同比下降12.95%，同时研发费用同比上升24.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"宣泰医药(688247.SH)发布半年度业绩，归母净利润2970万元，同比下降34.84%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657593579","title":"宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657593579?lang=zh_cn&edition=full","pubTime":"2026-08-05 07:30","pubTimestamp":1785886250,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日上海宣泰医药科技股份有限公司新提交“宣泰小红片”、“O'red”等3件商标注册申请。商标申请详情如下：今年以来上海宣泰医药科技股份有限公司新申请注册商标3件，截止目前公司共持有注册商标166件，另有21件商标尚在注册申请中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500007697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756567","title":"股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756567","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657756567?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:39","pubTimestamp":1785868751,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，宣泰医药报收于8.6元，上涨8.59%，换手率2.85%，成交量12.91万手，成交额1.07亿元。公司公告汇总自愿披露关于参与全国药品集中采购拟中选的公告上海宣泰医药科技股份有限公司参与第十二批全国药品集中采购，其产品注射用硫酸艾沙康唑和合作开发产品恩扎卢胺片拟中选，采购周期至2029年12月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656937424","title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656937424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656937424?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:38","pubTimestamp":1785764323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布公告，近日，公司参与了国家组织药品联合采购办公室组织的第十二批全国药品集中采购的投标，根据联采办于2026年7月31日在上海阳光医药采购网发布的《第12批国家组织药品集中带量采购拟中选结果公示》显示，公司产品注射用硫酸艾沙康唑、合作开发产品恩扎卢胺片拟中选本次集中采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654905773","title":"每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2654905773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654905773?lang=zh_cn&edition=full","pubTime":"2026-07-26 03:05","pubTimestamp":1785006313,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，宣泰医药报收于8.17元，较上周的8.91元下跌8.31%。本周，宣泰医药7月20日盘中最高价报9.11元。本周关注点来自机构调研要点：复杂制剂车间预充针生产线已具备正常运行能力，并成功开展试生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600001013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653086536","title":"宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653086536","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653086536?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:37","pubTimestamp":1784889478,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792461660127,"stockEarnings":[{"period":"1week","weight":-0.107},{"period":"1month","weight":-0.0703},{"period":"3month","weight":-0.0115},{"period":"6month","weight":-0.078},{"period":"1year","weight":-0.1755},{"period":"ytd","weight":-0.1122}],"compareEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":-0.0463},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0914},{"period":"1year","weight":-0.0283},{"period":"ytd","weight":-0.0599}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7693人(较上一季度减少3.41%)","perCapita":"58928股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、马昔腾坦片、美沙拉秦肠溶缓释片、西格列汀二甲双胍缓释片、格列净二甲双胍缓释片、奥拉帕利片、依西美坦片等。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}